Pemigatinib also showed durable and high rates of complete responses and complete cytogenetic responses in patients with relapsed or refractory myeloid/lymphoid neoplasms (RRMLN) with FGFR1 rearrangement in the phase II FIGHT-203 study, based on which it received FDA approval for FGFR1-rearranged RRMLN in 2022 [17]. Here, FGFR1 is linked to lymphoid neoplasm.